OUR STORY
We started IMCI because medical cannabis deserves pharma-grade standards.
Physicians and pharmacists can only rely on cannabinoid products that behave the same way, dose after dose. Many patients still smoke dried flower, which makes dosing imprecise and exposes them to the harms of inhaling smoke. Others use oils that are absorbed slowly and unevenly.
OUR PURPOSE
Smoke-free, precisely dosed formulations.
IMCI was founded to offer a better option: smoke-free, precisely dosed formulations. Our NanoVATE Delivery™ platform is built on research from the Hebrew University of Jerusalem, and every decision since has followed one rule: formulate and test medical cannabis to pharma-grade standards and build every product for EU-GMP manufacturing.
"I spent twenty years building and running companies. When I looked at medical cannabis, I saw strong demand and a product that patients and doctors could not fully trust. We set out to fix the product first."
Alon Hershkovitz
CEO & Co-Founder
HOW WE WORK
Standards that guide every decision.
Data first
We make claims only where published data or signed agreements stand behind them.
Built for regulation
Our formulations, supply routes and partnerships are designed around each market's medical cannabis rules from the start.
Consistency
Prescribers need a product that behaves the same way every time. That is what we formulate for.
FOUNDERS
Business experience meets
cannabinoid science.
Alon Hershkovitz
CEO & Co-Founder
20+ years in global enterprise leadership across four continents. Founded seven companies, led six M&A deals and three exits. MBA, Strategy & Entrepreneurship.
Avi Yakobovich
Executive Director, Business Development & Co-Founder
20+ years in business; former CEO of a multinational company. MBA, BA Economics, CPA.
Hagay Segev
Chief Commercial Officer
& Co-Founder
20+ years in pharma and medical cannabis; expert in go-to-market and marketing strategy.
LEADERSHIP TEAM
Experience across development
and operations.
David Blum
Chief Technology Officer
30+ years in pharma manufacturing, CMC and plant management.
Jonathan E. Friedman, Ph.D.
Chief Research & Development Officer
20+ years in CNS and pain pharmacology across pharma and biotech.
Gershon Ravid
Chief Operating Officer
21+ years leading HR and administration in the Israeli Navy (Lt. Col., ret.); recent years in the medical cannabis sector.
Jeff Wechsler
USA Business Development & Sales
14+ years in US cannabis, investments and operator network development.
SCIENTIFIC ADVISORY BOARD
Expertise behind the platform.
Prof. Igor Spigelman, Ph.D.
Scientific Development
30+ years in chronic pain, cannabinoid systems and novel analgesic development. University of California, Los Angeles (UCLA).
Prof. Abraham J. Domb, Ph.D.
Formulation Development
Former Chief Scientist, Israeli Ministry of Science & Technology; former Head, School of Pharmacy, Hebrew University. Expert in medicinal chemistry and biopolymers.
Joseph J. Morgan, M.D., AACM
Medical Director / Advisor
36+ years in pharma industry. Prof. of Cannabis Medicine, PA, NJ, USA. Cannabinoids & terpenes patent holder.
Dr. Arnon Aharon, M.D.
Clinical Development
15+ years in biotech clinical development across oncology, immunology, CNS and cannabinoid treatments.
IMCI in the news
TOP MEDICAL CANNABIS SERVICE PROVIDER IN EUROPE · JUNE 2023
IMCI recognised among Europe’s top medical cannabis service providers for 2023
TOP EU PHARMACEUTICAL STARTUPS, THE NETHERLANDS · AUGUST 2021
IMCI selected among the top EU pharmaceutical startups in the Netherlands
Read coverage →
STARTUS INSIGHTS · AUGUST 2021
Discover 5 Top HealthTechs Working on Pain Management Solutions
IMCI Pharmaceuticals is a commercial-stage pharmaceutical company. Product availability and regulatory status vary by market. Information on this website is not medical advice.